Xerosis and pruritus as major EGFRI-associated adverse events

Julia M K Clabbers, Christine B Boers-Doets, Hans Gelderblom, Theo Stijnen, Mario E Lacouture, Koos J M van der Hoeven, Adrian A Kaptein, Julia M K Clabbers, Christine B Boers-Doets, Hans Gelderblom, Theo Stijnen, Mario E Lacouture, Koos J M van der Hoeven, Adrian A Kaptein

Abstract

Purpose: The objective of this sub-analysis of the BeCet study (NCT01136005) was to examine health-related quality of life (HRQoL) of patients experiencing dermatological adverse events (AEs) during the first 6 weeks of epidermal growth factor receptor inhibitor (EGFRI) treatment.

Methods: Patients (n = 85) treated with EGFRI completed five questionnaires during the first 6 weeks of treatment. 77 patients provided enough data for the sub-analysis. Experienced AEs were reported in the Dermatological Reactions Targeted Therapy-Patients (DERETT-P), a symptom experience diary for patients treated with targeted therapy. The impact of EGFRI-associated dermatological adverse events on HRQoL was examined using four HRQoL questionnaires; the Functional Assessment of Cancer Therapy-EGFRI (FACT-EGFRI-18), the Functional Assessment of Cancer Therapy-General (FACT-G), the 36-Item Short Form Health Survey (SF-36), and the Skindex-16.

Results: During the first 6 weeks of EGFRI treatment, physical discomfort was the most significantly affected domain. In the entire study population, xerosis (dry skin) (22.3 %) and pruritus (itchy skin) (16.9 %) were reported as the most impactful AEs. For patients experiencing a papulopustular eruption (acneiform rash) pruritus (24.2 %), xerosis (18.9 %), and papulopustular eruption (6.3 %) were reported as the most impactful AEs. Papulopustular eruption, xerosis, and pruritus all showed a significant negative effect on HRQoL, displayed in FACT-EGFRI-18 scores.

Conclusions: In addition to papulopustular eruption, xerosis and pruritus are major EGFRI-associated dermatological AEs with an impact on HRQoL, which warrant more attention in clinical practice and research.

Keywords: Cancer; Epidermal growth factor receptor inhibitor; Papulopustular eruption; Pruritus; Quality of life; Xerosis.

Figures

Fig 1
Fig 1
a Adverse events that patients reported as present in DERETT-P compared to b adverse events as having most impact on HRQoL as measured by DERETT-P. In (a), papulopustular eruption is reported as the most common adverse event, while (b) displays that xerosis and pruritus have a more profound impact on HRQoL. HRQoL health-related quality of life
Fig. 2
Fig. 2
a Mean (standard error of the mean) FACT-EGFRI-18 total scores per week. b Mean (standard error of the mean) of all grade FACT-EGFRI-18 domain scores per week. c Mean (standard error of the mean) of grade 1/2 FACT-EGFRI-18 domain scores per week. d Mean (standard error of the mean) of grade 3/4 FACT-EGFRI-18 domain scores per week. FACT-EGFRI-18 Functional Assessment of Cancer Therapy–EGFRI, EGFRI epidermal growth factor receptor inhibitor

References

    1. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095. doi: 10.1007/s00520-011-1197-6.
    1. Abdullah SE, Haigentz M, Jr., Piperdi B (2012) Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemother Res Pract 2012:351210.doi: 10.1155/2012/351210
    1. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007;21(11 Suppl 5):34–36.
    1. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–3923. doi: 10.1002/cncr.25090.
    1. Boers-Doets CB, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. Eur J Oncol Nurs. 2013;17(6):802–807. doi: 10.1016/j.ejon.2013.03.004.
    1. Boers-Doets CB, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer. 2013;21(7):1919–1926. doi: 10.1007/s00520-013-1752-4.
    1. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390–5396. doi: 10.1200/JCO.2007.12.6987.
    1. Boers-Doets CB (2014) The Target System—approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. 1 ed. Wormer: IMPAQTT
    1. Wagner LI, Lai SE, Aneja M, LoRusso P, Perez-Soler R, O’Brien B et al. (2007) Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): the FAST-EGFRI. ASCO, Meeting Abstracts 25[18 Suppl], 19532.
    1. Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18) Support Care Cancer. 2013;21(4):1033–1041. doi: 10.1007/s00520-012-1623-4.
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579.
    1. Newnham EA, Harwood KE, Page AC. Evaluating the clinical significance of responses by psychiatric inpatients to the mental health subscales of the SF-36. J Affect Disord. 2007;98(1-2):91–97. doi: 10.1016/j.jad.2006.07.001.
    1. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–110. doi: 10.1007/BF02737863.
    1. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, Velde AtT, Verrips E (1998) Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 51(11):1055–1068
    1. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi: 10.1007/s40257-013-0021-0.
    1. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–1357. doi: 10.1200/JCO.2008.21.7828.
    1. Coleman S, Jatoi A. STEPP for the EGFR inhibitor-induced rash—definitely a step in the right direction. Curr Oncol Rep. 2010;12(4):223–225. doi: 10.1007/s11912-010-0102-7.
    1. Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors’ perspectives. Support Care Cancer. 2010;18(11):1461–1468. doi: 10.1007/s00520-009-0769-1.
    1. Frith H, Harcourt D, Fussell A. Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur J Oncol Nurs. 2007;11(5):385–391. doi: 10.1016/j.ejon.2007.03.002.
    1. White KJ, Roydhouse JK, Scott K. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment. Clin J Oncol Nurs. 2011;15(1):88–96. doi: 10.1188/11.CJON.88-96.
    1. Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011;50(2):129–146. doi: 10.1111/j.1365-4632.2010.04791.x.
    1. Haley AC, Calahan C, Gandhi M, West DP, Rademaker A, Lacouture ME. Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer. 2011;19(4):545–554. doi: 10.1007/s00520-010-0851-8.
    1. Siminoff LA. Improving communication with cancer patients. Oncology (Williston Park) 1992;6(10):83–87.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner